Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia

Phase

Condition

Pregnancy Complications

Preeclampsia

Hemorrhage

Treatment

aspirin discontinuation

aspirin continuation

Clinical Study ID

NCT06111079

[2023] Ethics Review NO.118

Ages 18-45
Female

Study Summary

Low-dose aspirin (LDA) is considered to be the most effective agent to prevent preeclampsia (PE). At present, there is little exploration about the timing of aspirin discontinuation. Most international guidelines default until 36 weeks of gestation or delivery. China Guideline (2020) recommended that aspirin should be preventively used until 26-28 weeks of gestation, but there was little direct evidence. According to the two-stage theory, placental dysplasia before 28 weeks of gestation is the key to developing PE, the significance of aspirin use after 28 weeks of gestation is debatable. If aspirin discontinuation at 28 weeks of gestation is proven to be feasible for preventing preterm PE, it will not only reduce the risk of Perinatal Haemorrhage but also save medical expenses.

Eligibility Criteria

Inclusion

Inclusion Criteria:

At <16 weeks of gestation, normal NT scan
At least 1 high risk factor or at least 2 moderate risk factors
Intend to receive prenatal examination and deliver in this institution
Signed a written informed consent for participation in the study

Exclusion

Exclusion Criteria:

Aspirin initiated after 16 week
Intolerant or allergic to aspirin
Aspirin adherence was <80%
Miscarriage or termination of pregnancy before randomization
drop out (do not return to the hospital for delivery).
Lost to follow-up

Study Design

aspirin discontinuation

November 01, 2023

December 31, 2024

Study Description

This study aimed to optimize the strategy of aspirin to prevent preeclampsia, by exploring whether aspirin discontinuation at 28 weeks of gestation to prevent preterm PE is not inferior to 36 weeks of gestation. We will include pregnant women with normal NT scan who meet at least one high-risk factor or at least two medium-risk factors. During 12-16 weeks of gestation, the mean arterial pressure (MAP) and placental growth factor (PlGF) are measured, then initiating aspirin 100mg qn. At 24-27+6 weeks of gestation, the patients were 1:1 randomly divided into two groups, sFlt-1 and PlGF were detected at the same time. The experimental group discontinue aspirin at 28 weeks of gestation, and the control group receive aspirin until 36 weeks of gestation. The incidence of preterm PE in the two groups was compared by non-inferiority test, and the non-inferiority threshold was 2%.

Connect with a study center

FANG HE
Guangzhou, Guangdong 510150
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.